



食道癌

召集人：陳右儒 主任

食道癌臨床治療準則

- 召集人：陳右儒主任

食道癌診療指引修訂

2025-01-08 修訂第十一版	2026-01-12 修訂第十一版
● 更新文獻 ● 新增食道癌診治共識-3特殊追蹤流程 ● 註4名詞修正 ● 新增、修訂共識處方 • 新增轉移後處方-Paclitaxel+Carboplatin triweekly、Irinotecan+Cisplatin	● 更新文獻 ● 修訂診斷共識內容 ● 新增食道癌TNM定義 • 新增鱗狀上皮細胞食道癌分期 • 新增食道腺癌分期 ● 修訂鱗狀上皮細胞癌治療共識-1至3 ● 新增食道癌腺癌治療共識-1至2 ● 修訂註1內容 ● 修訂共識處方

一、診斷共識

1. 必要性檢查及評估：

- (1) 病患病史及理學檢查
- (2) 消化道內視鏡檢查及病理切片
- (3) 胸/腹電腦斷層
- (4) 正子造影(還未證實已遠處轉移)
- (5) 基本血液檢查，包括全血球計數、凝血功能測試、生化檢查
- (6) 腫瘤位於carina以上，需安排支氣管鏡檢查。
- (7) 胃食道交界腫瘤需使用Siewert分類。
- (8) 營養指標、進食狀態評估諮詢。
- (9) 戒菸建議及藥物諮詢使用。
- (10) 家族史評估。
- (11) 腫瘤指數檢查，squamous cell carcinoma需測SCC、CEA、CA-199，adenocarcinoma需測CEA、CA-199

2. 選擇性檢查：

- (1) 骨盆腔電腦斷層
- (2) 內視鏡超音波(沒有已轉移，無法切除情況)。
- (3) 早期食道癌(Tis、T1a、T1b) 建議內視鏡切除。
- (4) 轉移性疾病若臨床許可考慮轉移病灶切片。
- (5) 所有新診斷的食道癌，應檢驗MSI、NGS、MMR、PD-L1。
- (6) 晚期或轉移性食道腺癌，考慮檢驗HER2、CLDN18.2。

3. 分期依據：

- (1) T的評估共識：以電腦斷層取最高階的T。
- (2) N的評估共識：以胸腔電腦斷層來評估及判斷正子掃描，有安排手術計畫者，需加做正子掃描評估。
- (3) 正子掃描確認有無遠端轉或淋巴結轉移。
- (4) 經多專科團隊會議確認臨床分期。
- (5) 臨床分期採用AJCC第八版分期標準。

二、食道癌TNM定義

Table 1. Definitions for T, N, M

T	Primary Tumor
TX	Primary tumor cannot be assessed
T0	No evidence of primary tumor
Tis	High-grade dysplasia, defined as malignant cells confined to the epithelium by the basement membrane
T1	Tumor invades the lamina propria, muscularis mucosae, or submucosa
T1a	Tumor invades the lamina propria or muscularis mucosae
T1b	Tumor invades the submucosa
T2	Tumor invades the muscularis propria
T3	Tumor invades adventitia
T4	Tumor invades adjacent structures
T4a	Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum
T4b	Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway
N	Regional Lymph Nodes
NX	Regional lymph nodes cannot be assessed
N0	No regional lymph node metastasis
N1	Metastasis in one or two regional lymph nodes
N2	Metastasis in three to six regional lymph nodes
N3	Metastasis in seven or more regional lymph nodes

M	Distant Metastasis
M0	No distant metastasis
M1	Distant metastasis
G	Histologic Grade
GX	Grade cannot be assessed
G1	Well differentiated
G2	Moderately differentiated
G3	Poorly differentiated, undifferentiated

Squamous Cell Carcinoma

Location	Location Criteria
X	Location unknown
Upper	Cervical esophagus to lower border of azygos vein
Middle	Lower border of azygos vein to lower border of inferior pulmonary vein
Lower	Lower border of inferior pulmonary vein to stomach, including gastroesophageal junction

Note: Location is defined by the position of the epicenter of the tumor in the esophagus.

鱗狀上皮細胞食道癌分期

Clinical Staging (cTNM)

	cT	cN	M
Stage 0	Tis	N0	M0
Stage I	T1	N0-1	M0
Stage II	T2	N0-1	M0
	T3	N0	M0
Stage III	T3	N1	M0
	T1-3	N2	M0
Stage IVA	T4	N0-2	M0
	Any T	N3	M0
Stage IVB	Any T	Any N	M1

Pathological (pTNM)

	pT	pN	M	G	Location
Stage 0	Tis	N0	M0	N/A	Any
Stage IA	T1a	N0	M0	G1	Any
	T1a	N0	M0	GX	Any
Stage IB	T1a	N0	M0	G2-3	Any
	T1b	N0	M0	G1-3	Any
	T1b	N0	M0	GX	Any
	T2	N0	M0	G1	Any
Stage IIA	T2	N0	M0	G2-3	Any
	T2	N0	M0	GX	Any
	T3	N0	M0	G1-3	Lower
	T3	N0	M0	G1	Upper/middle
Stage IIB	T3	N0	M0	G2-3	Upper/middle
	T3	N0	M0	GX	Lower/upper/middle
	T3	N0	M0	Any	Location X
	T1	N1	M0	Any	Any
Stage IIIA	T1	N2	M0	Any	Any
	T2	N1	M0	Any	Any
Stage IIIB	T2	N2	M0	Any	Any
	T3	N1-2	M0	Any	Any
	T4a	N0-1	M0	Any	Any
Stage IVA	T4a	N2	M0	Any	Any
	T4b	N0-2	M0	Any	Any
	Any T	N3	M0	Any	Any
Stage IVB	Any T	Any N	M1	Any	Any

Postneoadjuvant Therapy (ypTNM)

	ypT	ypN	M
Stage I	T0-2	N0	M0
Stage II	T3	N0	M0
Stage IIIA	T0-2	N1	M0
Stage IIIB	T3	N1	M0
	T0-3	N2	M0
	T4a	N0	M0
Stage IVA	T4a	N1-2	M0
	T4a	NX	M0
	T4b	N0-2	M0
	Any T	N3	M0
Stage IVB	Any T	Any N	M1

食道腺癌分期

Clinical Staging (cTNM)

	cT	cN	M
Stage 0	Tis	N0	M0
Stage I	T1	N0	M0
Stage IIA	T1	N1	M0
Stage IIB	T2	N0	M0
Stage III	T2	N1	M0
	T3	N0-1	M0
	T4a	N0-1	M0
Stage IVA	T1-4a	N2	M0
	T4b	N0-2	M0
	Any T	N3	M0
Stage IVB	Any T	Any N	M1

Pathological (pTNM)

	pT	pN	M	G
Stage 0	Tis	N0	M0	N/A
Stage IA	T1a	N0	M0	G1
	T1a	N0	M0	GX
Stage IB	T1a	N0	M0	G2
	T1b	N0	M0	G1-2
	T1b	N0	M0	GX
Stage IC	T1	N0	M0	G3
	T2	N0	M0	G1-2
Stage IIA	T2	N0	M0	G3
	T2	N0	M0	GX
Stage IIB	T1	N1	M0	Any
	T3	N0	M0	Any
Stage IIIA	T1	N2	M0	Any
	T2	N1	M0	Any
Stage IIIB	T2	N2	M0	Any
	T3	N1-2	M0	Any
	T4a	N0-1	M0	Any
Stage IVA	T4a	N2	M0	Any
	T4b	N0-2	M0	Any
	Any T	N3	M0	Any
Stage IVB	Any T	Any N	M1	Any


Postneoadjuvant Therapy (ypTNM)

	ypT	ypN	M
Stage I	T0-2	N0	M0
Stage II	T3	N0	M0
Stage IIIA	T0-2	N1	M0
Stage IIIB	T3	N1	M0
	T0-3	N2	M0
	T4a	N0	M0
Stage IVA	T4a	N1-2	M0
	T4a	NX	M0
	T4b	N0-2	M0
	Any T	N3	M0
Stage IVB	Any T	Any N	M1


三、鱗狀上皮細胞癌治療共識

Squamous cell carcinoma(SCC)


三、鱗狀上皮細胞食道癌診治共識-1



三、鱗狀上皮細胞食道癌診治共識-2




三、鱗狀上皮細胞食道癌診治共識-3




四、食道腺癌治療共識

Adenocarcinomas

四、食道腺癌腺癌診治共識-1



四、食道腺癌腺癌診治共識-2



註1：不適合手術切除：無法手術切除：經評估後，個案本身慢性疾病易造成合併症或年紀過大等因素。

註2：追蹤共識：

1. 治療期完成後建議前兩年至少每三個月須回門診追蹤，追蹤tumor markers and chest CT。
2. 僅接受內視鏡切除之病患，術後第一年每三個月追蹤內視鏡。
3. 第三年開始，每六個月回門診追蹤一次，滿五年後每年回診。
4. 緩和照顧期至少三個月追蹤。

註3：高風險病灶：

LVI：lymphovascular invasion

分化不良

註4：前導性放射線治療及化學治療：preoperative CCRT

同步放射線治療及化學治療：definitive CCRT

註5：pTis, pT1a，內視鏡切除優於食道切除

五、治療共識

1. 分期治療準則：

- (1).建議治療計畫是在團隊討論下形成。
- (2).若病人進行治療前已發生吞嚥困難，應先建立其他腸道營養灌食管道，以空腸造瘻為優先考慮並持續評估營養狀態。
- (3).臨床分期Tis、T1a，N0，M0可考慮直接進行手術切除。
- (4).T1b，any N的cervical Esophageal cancer建議做CCRT。
- (5).T4b，any N建議做neoadjuvant CCRT或definitive CCRT。
- (6).接受neoadjuvant C/T治療後的SqCC病人儘可能手術切除，無法切除者才考慮做C/T。
- (7).直接手術或有先接受neoadjuvant CCRT治療的SqCC術後R0 Resection者:不管N(+)或(-)都先採追蹤觀察。
- (8).SqCC術後R0 Resection者:病理N0與病理N+，皆觀察即可。
- (9).Unresectable的病人應盡量進行CCRT，無法同時者擇其一(C/T or R/T)。
- (10).Metastasis的病人，若ECOG $\leq$ 2分，建議採緩和治療及支持性療法。

2. 手術治療：

- (1)食道癌的手術由外科醫師依肺功能、病人年齡、身體功能來評估。
- (2)術前輔助治療完成後，需再進行胸部電腦斷層評估分期改變。
- (3)VATS可視為有效的根治性切除方式。
- (4)手術切除應儘可能摘取15顆以上的局部淋巴結取樣。

六、追蹤共識

1. 首次治療完成後，建議前2年至少每3個月需回門診追蹤。
2. 追蹤必要項目為胸部電腦斷層、腫瘤指數、基本生化檢查，視病情需要加排腦部電腦斷層、骨頭掃瞄或正子掃瞄。
3. 第三年開始每6個月回門診追蹤一次。
4. 第六年開始每年回門診追蹤一次。

七、食道癌化療共識處方

Preoperative Chemoradiation of Esophageal cancer

化療系統 處方代碼	處方	藥名	劑量 (mg/m ²)	途徑	輸注時間	天數	頻率	療程數	文獻
Y001	Paclitaxel+ Carboplatin	Paclitaxel	50	IVD		D1	QW	5	3
		Carboplatin	AUC2	IVD		D1			
	Cisplatin+ 5-FU (Q4W)	Cisplatin	75	IVD	24	D1	Q4W	2(RT)+2	4
		Fluorouracil	1000	IVD		D1-4			
	(PreOP)PF regimen Triweekly	Cisplatin	15	IVD		D1-5	Q3W	2	5
		Fluorouracil	800	IVD	24	D1-5			
	Cisplatin+ Capecitabine	Capecitabine	800	PO	BID	D1-5	QW	5	6
		Cisplatin	30	IVD		D1			

七、食道癌化療共識處方

Preoperative Chemoradiation of Esophageal cancer

化療系統 處方代碼	處方	藥名	劑量 (mg/m ²)	途徑	輸注時間	天數	頻率	療程數	文獻
Oxalip+5-FU		Oxaliplatin	50	IVD		D1			
		Leucovorin	400	IVD		D1			
		Fluorouracil	400	IVD		D1	Q4W	3(RT)+3	5
		Fluorouracil	800	IVD	24h	D1-2			
Oxalip+ Capecitabine		Oxaliplatin	85	IVD		D1,15,29	3 doses		
		Capecitabine	625	PO		D1-5	QW	5	7
Irinotecan+ Cisplatin		Irinotecan	65	IVD					
		Cisplatin	30	IVD		D1,8,22,29		1	8
Paclitaxel+ 5-FU		Paclitaxel	50	IVD		D1			
		Fluorouracil	300	IVD		D1-5	QW	5	9

七、食道癌化療共識處方

Preoperative Chemoradiation (Adenocarcinoma of thoracic esophagus or EGJ)

化療系統 處方代碼	處方	藥名	劑量 (mg/m ²)	途徑	輸注時間	天數	頻率	療程數	文獻
	Cisplatin+	Cisplatin	80	IVD		D1			
	5-FU	Fluorouracil	1000	IVD	24h	D1-4	Q3W	2(pre-op)	23

七、食道癌化療共識處方

Perioperative Chemotherapy (Include EGJ)

化療系統 處方代碼	處方	藥名	劑量 (mg/m ²)	途徑	輸注時間	天數	頻率	療程數	文獻
FLOT		Oxaliplatin	85	IVD	2h	D1	Q2W	4(pre-op)+ 4(post-op)	30
		Leucovorin	200	IVD	2h	D1			
		Fluorouracil	2600	IVD	24	D1			
		Docetaxel	50	IVD	1.5h	D1			
FLO		Oxaliplatin	85	IVD	2h	D1	Q2W	4(pre-op)+ 4(post-op)	18
		Leucovorin	200	IVD	2h	D1			
		Fluorouracil	2600	IVD	24	D1			
CAPOX		Oxaliplatin	85	IVD	2h	D1	Q3W		17
		Capecitabine	2000	PO	BID	D1-14			

七、食道癌化療共識處方

dCRT (definite chemoradiotherapy)

化療系統 處方代碼	處方	藥名	劑量 (mg/m ²)	途徑	輸注時間	天數	頻率	療程數	文獻
Y002 Y002-1	PF	Cisplatin	75	IVD	4h	D1	Q4W	The first 2 cycles R/T+ 2 cycles after R/T	1
		Leucovorin	100	IVD	12h	D1-4			
		Fluorouracil	1000	IVD	20h	D1-4			
Y002-2 Y002-3	Carboplatin+ 5-FU	Carboplatin	AUC5	IVD	4h	D1	Q4W	The first 2 cycles R/T+ 2 cycles after R/T	31-33
		Leucovorin	100	IVD	12h	D1-4			
		Fluorouracil	1000	IVD	20h	D1-4			
Y003	PFL	Cisplatin	80	IVD	2h	D1	Week1,5, 8,11		24
		Leucovorin	90	IVD	20h	D1-4			
		Fluorouracil	800	IVD	20h	D1-4			
Y004	Cisplatin	Cisplatin	30	IVD	2h	D1	QW	5-6	27
	Carboplatin	AUC2	IVD	IVD	2h	D1	QW	7	25

七、食道癌化療共識處方

Postoperative Chemotherapy

化療系統 處方代碼	處方	藥名	劑量 (mg/m ²)	途徑	輸注時間	天數	頻率	療程數	文獻
	Oxalipl+ Capecitabine	Oxaliplatin	130	IVD	2h	D1	Q3W		19
		Capecitabine	1000	PO	BID	D1-14			
	Oxaliplatin+ 5-FU	Oxaliplatin	85	IVD	2h	D1	Q2W		29
		Leucovorin	400	IVD	2h	D1			
		Fluorouracil	400	IVP	15min	D1			
		Fluorouracil	1200	IVD	24h	D1-2			

七、食道癌化療共識處方

Postoperative Chemotherapy

化療系統 處方代碼	處方	藥名	劑量 (mg/m ²)	途徑	輸注時間	天數	頻率	療程數	文獻
Leucovorin+ 5-FU	Leucovorin	400	IVD			D1		The first 2 before RT+4 after RT	20
	Fluorouracil	400	IVD			D1	Q2W		
	Fluorouracil	1200	IVD		24h	D1-2			
5-FU (with radiation)	Fluorouracil	200-250	IVD		24h	D1-5	QW	5 with RT	21
Capecitabine	Capecitabine	625-825	PO		BID	D1-5	QW	5 with RT	22

七、食道癌化療共識處方

Chemotherapy for Advanced Esophageal cancer (1st-line)

化療系統 處方代碼	處方	藥名	劑量 (mg/m ²)	途徑	輸注時間	天數	頻率	療程數	文獻
Y008	Trastuzumab (+chemotherapy)	Trastuzumab	8 → 6 mg/kg	IVD			Q3W		10
		Trastuzumab	6 → 4 mg/kg	IVD			Q2W		
	Oxaliplatin+5-FU	Oxaliplatin	85	IVD	2h	D1	Q2W		11
		Leucovorin	400	IVD	2h	D1			
		Fluorouracil	400	IVP	15min	D1			
		Fluorouracil	1200	IVD	24h	D1-2			
	Oxaliplatin+ Capecitabine	Oxaliplatin	130	IVD	2h	D1	Q3W		12
		Capecitabine	1000	PO	BID	D1-14			
	Cisplatin+ Fluorouracil	Cisplatin	75-100	IVD		D1	Q4W		13
		Fluorouracil	750-1000	IVD		D1-4			
	Cisplatin+ Capecitabine	Cisplatin	80	IVD		D1	Q3W		14
		Capecitabine	1000	PO	BID	D1-14			

七、食道癌化療共識處方

Chemotherapy for Advanced Esophageal cancer (1st-line)

化療系統 處方代碼	處方	藥名	劑量 (mg/m ²)	途徑	輸注時間	天數	頻率	療程數	文獻
Y011	CARBOplatin(AUC5) +Capecitabine	CARBOplatin	AUC5	IVD		D1	Q3W		36
		Capecitabine	1000	PO	BID	D1-14			

七、食道癌化療共識處方

Chemotherapy for Advanced Esophageal cancer (1st-line)

化療系統 處方代碼	處方	藥名	劑量 (mg/m ²)	途徑	輸注時間	天數	頻率	療程數	文獻
Y007	DCF regimen	Docetaxel	40	IVD	1h	D1	Q2W		28
		Cisplatin	40	IVD	4h	D1			
		Leucovorin	400	IVP	1h	D1			
		Fluorouracil	1000	IVD	24h	D1-2			

七、食道癌化療共識處方

Chemotherapy for Advanced Esophageal cancer (1st-line)

化療系統 處方代碼	處方	藥名	劑量 (mg/m ²)	途徑	輸注時間	天數	頻率	療程數	文獻
	Pembrolizumab (SCC, MSI-H/dMMR)	Pembrolizumab	200mg	IVD		D1	Q3W		15
	Nivolumab (SCC)	Nivolumab	240mg	IVD		D1	Q2W		16

七、食道癌化療共識處方

Chemotherapy for Advanced Esophageal cancer (other regimens)

化療系統 處方代碼	處方	藥名	劑量 (mg/m ²)	途徑	輸注時間	天數	頻率	療程數	文獻
Y005 Y005-1	Carboplatin +Paclitaxel	Paclitaxel	60	IVD	2h	D1,8,15	Q4W		2
		Carboplatin	AUC5	IVD	1h	D1			
Y009	Carboplatin +Paclitaxel	Paclitaxel	200	IVD	2h	D1	Q3W		34
		Carboplatin	AUC5	IVD	1h	D1			
Y006	Paclitaxel triweekly	Paclitaxel	135–250	IVD		D1	Q3W		26
Y010	Irinotecan +Cisplatin	Irinotecan	65	IVD	2h	D1,8	Q3W		35
		Cisplatin	25-30	IVD	1h	D1,8			
Y012	CAPOX	Oxaliplatin	85	IVD	2h	D1	Q3W		37
		Capecitabine	625	PO	BID	D1-14			

八、食道癌放射線治療政策與程序指引

參考本院放射線治療指引

九、參考資料

(一)診療指引參考文獻

1. NCCN Clinical Practice in Oncology: Esophagus and esophagogastric junction cancers. V4.2025
2. 9th AJCC

(二)化療共識處方參考文獻

1. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999;281(17):1623-1627. doi:10.1001/jama.281.17.1623
2. G. K. Prithviraj K. Baksh W. Fulp et al. (2015). Carboplatin and paclitaxel as first-line treatment of unresectable or metastatic esophageal or gastric cancer. Diseases of the esophagus, 28: 782–787.
3. Van Hagen P, Hulshof MC, van Lanschot, J.J, et al. Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer. N Engl J Med 2012;366:2074-2084.
4. Conroy T, Galais MP, Raoul JL, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol 2014;15:305-314.
5. Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007; 25:1160-1168.
6. Lee SS, Kim SB, Park SI, et al. Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer. Jpn J Clin Oncol 2007;37:829-835.
7. Javle MM, Yang G, Nwogu CE, et al. Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis. Cancer Invest 2009;27:193-200.
8. Sharma R, Yang GY, Nava HR, et al. A single institution experience with neoadjuvant chemoradiation (CRT) with irinotecan (I) and cisplatin (C) in locally advanced esophageal carcinoma (LAEC) [abstract]. J Clin Oncol 2009;27 (Suppl 15):Abstract e15619.
9. Ajani JA, Winter K, Okawara GS, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol 2006;24:3953-3958.

10. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial. *Lancet* 2010;376:687-697.
11. Enzinger PC, Burtneß B, Hollis D, et al. CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer [abstract]. *J Clin Oncol* 2010;28 (Suppl 15):Abstract 4006.
12. Kim GM, Jeung HC, Rha SY, et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. *Eur J Cancer* 2012;48:518-526.
13. Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. *Ann Oncol* 2009;20:1667-1673.
14. Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. *Ann Oncol* 2009;20:666-673.
15. Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol* 2019;20:1506-1517.
16. Kojima T, Shah MA, Muro K, et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. *J Clin Oncol* 2020;38:4138-4148.
17. Kim GM, Jeung HC, Rha SY, et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. *Eur J Cancer* 2012;48:518-526.
18. Al-Batran S-E, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. *J Clin Oncol* 2008;26:1435-1442.
19. Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomized phase 3 trial. *Lancet Oncol* 2014; 15:1389-1396.
20. National Comprehensive Cancer Networks (NCCN) (2022). NCCN clinical practice guidelines in esophageal and esophagogastric junction cancers. Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf
21. Leong T, Joon DL, Willis D, et al. Adjuvant chemoradiation for gastric cancer using epirubicin, cisplatin, and 5-fluorouracil before and after three-dimensional conformal radiotherapy with concurrent infusional 5-fluorouracil: a multicenter study of the trans-tasman radiation oncology group. *Int J Radiat Oncol Biol Phys* 2011;79:690-695.
22. Lee HS, Choi Y, Hur WJ, et al. Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation with capecitabine. *World J Gastroenterol* 2006;12:603-607.
23. Alderson D, Cunningham D, Nankivell M, et al. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with esophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. *Lancet Oncol*. 2017;18(9):1249-1260. doi:10.1016/S1470-2045(17)30447-3.
24. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. *JAMA*. 1999;281(17):1623-1627. doi:10.1001/jama.281.17.1623

25. Bhandari V. Role of concurrent chemoradiation in inoperable carcinoma esophagus: a prospective study. *J Cancer Res Ther.* 2014;10(1):11-14. doi:10.4103/0973-1482.131330
26. Ajani JA, Ilson DH, Daugherty K, et al. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. *J Natl Cancer Inst* 1994;86:1086-1091.
27. Bhandari V. Role of concurrent chemoradiation in inoperable carcinoma esophagus: a prospective study. *J Cancer Res Ther.* 2014 Jan-Mar;10(1):11-4. doi: 10.4103/0973-1482.131330. PMID: 24762479.
28. Shah MA, Janjigian YY, Stoller R, et al. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. *J Clin Oncol.* 2015;33(33):3874-3879. doi:10.1200/JCO.2015.60.7465
29. Enzinger PC, Burtneis BA, Niedzwiecki D, et al. CALGB 80403 (Alliance)/E1206: a randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal junction cancers. *J Clin Oncol* 2016;34:2736-2742
30. Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. *Lancet.* 2019;393(10184):1948-1957. doi:10.1016/S0140-6736(18)32557-1
31. Conroy T, Galais MP, Raoul JL, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGES/ACCORD17): final results of a randomised, phase 2/3 trial. *Lancet Oncol* 2014;15:305-314.
32. Qu XM, Biagi JJ, Hopman WM, Mahmud A. Shifting practice in definitive chemoradiation for localized esophageal cancer. *Curr Oncol.* 2017;24(5):e379-e387. doi:10.3747/co.24.3677
33. Hanemaaijer SH, Kok IC, Fehrmann RSN, et al. Comparison of Carboplatin With 5-Fluorouracil vs. Cisplatin as Concomitant Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. *Front Oncol.* 2020;10:761. Published 2020 Jun 5. doi:10.3389/fonc.2020.00761
34. Gadgeel SM, Shields AF, Heilbrun LK, et al. Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. *Am J Clin Oncol* 2003;26:37-41.
35. Ilson DH. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. *Oncology (Williston Park)* 2004;18:22-25.
36. Kang, Y. K., Kang, W. K., Shin, D. B., Chen, J., Xiong, J., Wang, J., Lichinitser, M., Guan, Z., Khasanov, R., Zheng, L., Philco-Salas, M., Suarez, T., Santamaria, J., Forster, G., & McCloud, P. I. (2009). Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. *Annals of oncology : official journal of the European Society for Medical Oncology*, 20(4), 666–673. <https://doi.org/10.1093/annonc/mdn717>
37. Zekri J, Baghdadi MA, Ibrahim RB, Meliti A, Sobahy TM. Biweekly cetuximab in combination with capecitabine and oxaliplatin (XELOX) or irinotecan (XELIRI) in the first-line and second-line treatment of patients with RAS wild-type metastatic colorectal cancer. *Eancernermedicalscience.* 2022;16:1490. Published 2022 Dec 15. doi:10.3332/ecancer.2022.1490

本治療指引將每年檢討修訂一次
若有未詳述之內容，請參閱NCCN guideline.
預定下次修訂日期：**2026**年12月

